Big news in global pharma 💊: on Wednesday (November 26), French firm Pierre Fabre Laboratories signed a landmark deal with China's Sinopharm to advance the commercialization and localization of its anti-cancer drugs in the Chinese mainland.
This partnership is the first major agreement in the Chinese mainland since Marie-Andree Gamache took the helm as CEO of Pierre Fabre Medical Care earlier this year. By working closely with a leading local partner, the company aims to streamline clinical trials, speed up approvals, and boost domestic manufacturing capabilities.
Gamache told CGTN that Pierre Fabre sees fresh opportunities in China, with the country set to launch its 15th Five-Year Plan (2026-2030) next year. Investors and patients alike are watching as this move could mean faster access to innovative therapies and a stronger biotech ecosystem across the region 🚀🌏.
This deal shows how cross-border collaborations are reshaping the future of medicine in Asia and beyond. The world will be watching as these new therapies reach patients across the Chinese mainland.
Reference(s):
French pharmaceutical giant strengthens investments in China
cgtn.com
